Pellet manufacturing by extrusion-spheronization using process analytical technology

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Pellet manufacturing by extrusion-spheronization using process analytical technology. / Sandler, Niklas; Rantanen, Jukka; Heinämäki, Jyrki; Römer, Meike; Marvola, Martti; Yliruusi, Jouko.

In: AAPS PharmSciTech, Vol. 6, No. 2, 2005, p. E174-83.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Sandler, N, Rantanen, J, Heinämäki, J, Römer, M, Marvola, M & Yliruusi, J 2005, 'Pellet manufacturing by extrusion-spheronization using process analytical technology', AAPS PharmSciTech, vol. 6, no. 2, pp. E174-83. https://doi.org/10.1208/pt060226

APA

Sandler, N., Rantanen, J., Heinämäki, J., Römer, M., Marvola, M., & Yliruusi, J. (2005). Pellet manufacturing by extrusion-spheronization using process analytical technology. AAPS PharmSciTech, 6(2), E174-83. https://doi.org/10.1208/pt060226

Vancouver

Sandler N, Rantanen J, Heinämäki J, Römer M, Marvola M, Yliruusi J. Pellet manufacturing by extrusion-spheronization using process analytical technology. AAPS PharmSciTech. 2005;6(2):E174-83. https://doi.org/10.1208/pt060226

Author

Sandler, Niklas ; Rantanen, Jukka ; Heinämäki, Jyrki ; Römer, Meike ; Marvola, Martti ; Yliruusi, Jouko. / Pellet manufacturing by extrusion-spheronization using process analytical technology. In: AAPS PharmSciTech. 2005 ; Vol. 6, No. 2. pp. E174-83.

Bibtex

@article{c84098ea11a1480f9b4600cd63a0a777,
title = "Pellet manufacturing by extrusion-spheronization using process analytical technology",
abstract = "The aim of this study was to investigate the phase transitions occurring in nitrofurantoin and theophylline formulations during pelletization by extrusion-spheronization. An at-line process analytical technology (PAT) approach was used to increase the understanding of the solid-state behavior of the active pharmaceutical ingredients (APIs) during pelletization. Raman spectroscopy, near-infrared (NIR) spectroscopy, and X-ray powder diffraction (XRPD) were used in the characterization of polymorphic changes during the process. Samples were collected at the end of each processing stage (blending, granulation, extrusion, spheronization, and drying). Batches were dried at 3 temperature levels (60 degrees C, 100 degrees C, and 135 degrees C). Water induced a hydrate formation in both model formulations during processing. NIR spectroscopy gave valuable real-time data about the state of water in the system, but it was not able to detect the hydrate formation in the theophylline and nitrofurantoin formulations during the granulation, extrusion, and spheronization stages because of the saturation of the water signal. Raman and XRPD measurement results confirmed the expected pseudopolymorphic changes of the APIs in the wet process stages. The relatively low level of Raman signal with the theophylline formulation complicated the interpretation. The drying temperature had a significant effect on dehydration. For a channel hydrate (theophylline), dehydration occurred at lower drying temperatures. In the case of isolated site hydrate (nitrofurantoin), dehydration was observed at higher temperatures. To reach an understanding of the process and to find the critical process parameters, the use of complementary analytical techniques are absolutely necessary when signals from APIs and different excipients overlap each other.",
keywords = "Chemistry, Pharmaceutical, Drug Implants, Freeze Drying, Humidity, Pharmaceutical Preparations, Spectroscopy, Near-Infrared, Technology, Pharmaceutical",
author = "Niklas Sandler and Jukka Rantanen and Jyrki Hein{\"a}m{\"a}ki and Meike R{\"o}mer and Martti Marvola and Jouko Yliruusi",
year = "2005",
doi = "10.1208/pt060226",
language = "English",
volume = "6",
pages = "E174--83",
journal = "AAPS PharmSciTech",
issn = "1530-9932",
publisher = "Springer",
number = "2",

}

RIS

TY - JOUR

T1 - Pellet manufacturing by extrusion-spheronization using process analytical technology

AU - Sandler, Niklas

AU - Rantanen, Jukka

AU - Heinämäki, Jyrki

AU - Römer, Meike

AU - Marvola, Martti

AU - Yliruusi, Jouko

PY - 2005

Y1 - 2005

N2 - The aim of this study was to investigate the phase transitions occurring in nitrofurantoin and theophylline formulations during pelletization by extrusion-spheronization. An at-line process analytical technology (PAT) approach was used to increase the understanding of the solid-state behavior of the active pharmaceutical ingredients (APIs) during pelletization. Raman spectroscopy, near-infrared (NIR) spectroscopy, and X-ray powder diffraction (XRPD) were used in the characterization of polymorphic changes during the process. Samples were collected at the end of each processing stage (blending, granulation, extrusion, spheronization, and drying). Batches were dried at 3 temperature levels (60 degrees C, 100 degrees C, and 135 degrees C). Water induced a hydrate formation in both model formulations during processing. NIR spectroscopy gave valuable real-time data about the state of water in the system, but it was not able to detect the hydrate formation in the theophylline and nitrofurantoin formulations during the granulation, extrusion, and spheronization stages because of the saturation of the water signal. Raman and XRPD measurement results confirmed the expected pseudopolymorphic changes of the APIs in the wet process stages. The relatively low level of Raman signal with the theophylline formulation complicated the interpretation. The drying temperature had a significant effect on dehydration. For a channel hydrate (theophylline), dehydration occurred at lower drying temperatures. In the case of isolated site hydrate (nitrofurantoin), dehydration was observed at higher temperatures. To reach an understanding of the process and to find the critical process parameters, the use of complementary analytical techniques are absolutely necessary when signals from APIs and different excipients overlap each other.

AB - The aim of this study was to investigate the phase transitions occurring in nitrofurantoin and theophylline formulations during pelletization by extrusion-spheronization. An at-line process analytical technology (PAT) approach was used to increase the understanding of the solid-state behavior of the active pharmaceutical ingredients (APIs) during pelletization. Raman spectroscopy, near-infrared (NIR) spectroscopy, and X-ray powder diffraction (XRPD) were used in the characterization of polymorphic changes during the process. Samples were collected at the end of each processing stage (blending, granulation, extrusion, spheronization, and drying). Batches were dried at 3 temperature levels (60 degrees C, 100 degrees C, and 135 degrees C). Water induced a hydrate formation in both model formulations during processing. NIR spectroscopy gave valuable real-time data about the state of water in the system, but it was not able to detect the hydrate formation in the theophylline and nitrofurantoin formulations during the granulation, extrusion, and spheronization stages because of the saturation of the water signal. Raman and XRPD measurement results confirmed the expected pseudopolymorphic changes of the APIs in the wet process stages. The relatively low level of Raman signal with the theophylline formulation complicated the interpretation. The drying temperature had a significant effect on dehydration. For a channel hydrate (theophylline), dehydration occurred at lower drying temperatures. In the case of isolated site hydrate (nitrofurantoin), dehydration was observed at higher temperatures. To reach an understanding of the process and to find the critical process parameters, the use of complementary analytical techniques are absolutely necessary when signals from APIs and different excipients overlap each other.

KW - Chemistry, Pharmaceutical

KW - Drug Implants

KW - Freeze Drying

KW - Humidity

KW - Pharmaceutical Preparations

KW - Spectroscopy, Near-Infrared

KW - Technology, Pharmaceutical

U2 - 10.1208/pt060226

DO - 10.1208/pt060226

M3 - Journal article

C2 - 16353975

VL - 6

SP - E174-83

JO - AAPS PharmSciTech

JF - AAPS PharmSciTech

SN - 1530-9932

IS - 2

ER -

ID: 140622369